{"id":520215,"date":"2021-07-29T16:05:13","date_gmt":"2021-07-29T20:05:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-reports-second-quarter-2021-financial-results-and-operational-highlights\/"},"modified":"2021-07-29T16:05:13","modified_gmt":"2021-07-29T20:05:13","slug":"lantern-pharma-reports-second-quarter-2021-financial-results-and-operational-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lantern-pharma-reports-second-quarter-2021-financial-results-and-operational-highlights\/","title":{"rendered":"Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights"},"content":{"rendered":"
\n

– Obtained positive preclinical data in pancreatic cancer showing a significant reduction, averaging 93%, in tumor volume in in-vivo animal models from research collaboration with Fox Chase Cancer Center<\/h2>\n

– Preparing clinical trial site selection and finalization of initial GMP drug material batch during Q3 for LP-300 phase 2 clinical trial in non-small cell lung cancer<\/h2>\n

– Validated LP-184’s potential as a synthetic lethal agent in HRD (homologous recombination deficient) and NERD (nucleotide excision repair deficient) cancers<\/h2>\n

– Initiated targeted validation of new molecule, LP-284, in lymphomas<\/h2>\n

– Strengthened intellectual property portfolio with filing of 11 new patent applications, including 2 for the RADR platform<\/h2>\n

– RADR\u00ae A.I. platform continues rapid development with additional focus on hematological cancers and expansion of machine learning functionality<\/h2>\n

– $79.6 million in cash, cash equivalents and marketable securities as of June 30, 2021<\/h2>\n

– Conference call scheduled for 4:30 p.m. ET today<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n DALLAS<\/span>, July 29, 2021<\/span> \/PRNewswire\/ — Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern”), a clinical stage biopharmaceutical company using its proprietary RADR<\/i>\u00ae <\/sup>artificial intelligence (“A.I.”) platform to transform oncology drug discovery and development today announced financial results for the second quarter ended June 30, 2021<\/span>. <\/p>\n

\n

\n
\n \"Lantern
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“We are committed to bringing our pipeline of targeted cancer therapies to patients faster by utilizing our RADR\u00ae<\/sup> A.I. platform and making continual advances in our portfolio,” stated Panna Sharma<\/span>, President and CEO of Lantern Pharma. “This past quarter we made significant advances in our LP-184 program in pancreatic cancer and in validating the role this potent molecule can play in being synthetically lethal in cancers with DNA repair deficiencies. This opens up opportunities for LP-184 in several additional cancers, such as bladder and ovarian, and as a potential combination agent with existing PARP inhibitors.” <\/p>\n

“With the recently announced reacquisition of LP-100 earlier this week, we will use insights from the LP-100 trial and investigators to assess further enrollment of the Phase 2 trial in Denmark<\/span> and initiation of other studies where LP-100 can play a role as a potential cancer therapy. We believe this molecule has the potential to address a market of nearly $200 million<\/span> in the U.S. and approximately $700 million<\/span> globally.”<\/p>\n

Lantern is developing four drug candidates and an ADC program across eight disclosed indications, including:<\/p>\n